Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency
Background: Dose adjustment or laboratory monitoring of low-molecular-weight heparin
(LMWH) is commonly recommended for patients with severe renal insufficiency (creatinine …
(LMWH) is commonly recommended for patients with severe renal insufficiency (creatinine …
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
J Hirsh, R Raschke - Chest, 2004 - Elsevier
This article about unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH)
is part of the Seventh American College of Chest Physicians Conference on Antithrombotic …
is part of the Seventh American College of Chest Physicians Conference on Antithrombotic …
Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines
This chapter describes the pharmacology of approved parenteral anticoagulants, including
the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins …
the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins …
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
GJCM Sanderink, CG Guimart, ML Ozoux… - Thrombosis research, 2002 - Elsevier
The pharmacokinetics of the low-molecular-weight heparin enoxaparin were evaluated in 12
healthy volunteers and 36 patients with mild, moderate or severe renal impairment …
healthy volunteers and 36 patients with mild, moderate or severe renal impairment …
Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice
J Fareed, D Hoppensteadt, J Walenga, O Iqbal… - Clinical …, 2003 - Springer
Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from
unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties …
unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties …
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE …
SA Spinler, SM Inverso, M Cohen, SG Goodman… - American heart …, 2003 - Elsevier
BACKGROUND: The advantages of enoxaparin over unfractionated heparin (UFH) for the
treatment of patients with non-ST-segment elevation acute coronary syndromes are well …
treatment of patients with non-ST-segment elevation acute coronary syndromes are well …
Dosage of enoxaparin among obese and renal impairment patients
A Bazinet, K Almanric, C Brunet, I Turcotte… - Thrombosis research, 2005 - Elsevier
BACKGROUND: Enoxaparin dosage for obese patients and patients with renal impairment
remains controversial. OBJECTIVE: To compare anti-factor Xa activity (anti-Xa) among …
remains controversial. OBJECTIVE: To compare anti-factor Xa activity (anti-Xa) among …
Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study
M Joannidis, J Kountchev, M Rauchenzauner… - Intensive care …, 2007 - Springer
Objective The purpose of this study was to evaluate the efficacy and safety of the low
molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous …
molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous …
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin
N Thorevska, Y Amoateng-Adjepong, R Sabahi… - Chest, 2004 - Elsevier
Objectives To compare the rates of bleeding complications in patients with renal
insufficiency who receive anticoagulation therapy with the full therapeutic dose …
insufficiency who receive anticoagulation therapy with the full therapeutic dose …